8-K Announcements
6Material company update
Mar 31, 2026·SEC
Material company update
Mar 3, 2026·SEC
Material company update
Mar 3, 2026·SEC
Tharimmune, Inc.(THAR)Earnings, Financials & Key Ratios
THAR•NASDAQ
$3.54
$140M mkt cap·Price updated May 6, 2026
AboutTharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.Show more
- Revenue$0
- EBITDA-$13M-36.1%
- Net Income-$12M-30.9%
- EPS (Diluted)-9.41+91.2%
- ROE-233.69%-84.0%
- Interest Coverage-908.64-58.6%
THAR Key Insights
Tharimmune, Inc. (THAR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
THAR Price & Volume
Tharimmune, Inc. (THAR) stock price & volume — 10-year historical chart
Loading chart...
THAR Growth Metrics
Tharimmune, Inc. (THAR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM4.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM64.16%
Return on Capital
10 Years-403.54%
5 Years-403.54%
3 Years-403.54%
Last Year-238.22%
THAR Recent Earnings
Tharimmune, Inc. (THAR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (22%)
Q2 2026Latest
Mar 31, 2026EPS
$0.79
Est $0.42
-88.1%
Revenue
—
Q2 2026
Mar 24, 2026EPS
$2.02
Est $0.42
-381.0%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$0.34
Est $0.43
+20.9%
Revenue
—
Q3 2025
Aug 14, 2025EPS
$0.64
Est $0.58
-10.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 31, 2026 | $0.79vs $0.42-88.1% | — |
| Q2 2026 | Mar 24, 2026 | $2.02vs $0.42-381.0% | — |
| Q4 2025 | Nov 12, 2025 | $0.34vs $0.43+20.9% | — |
| Q3 2025 | Aug 14, 2025 | $0.64vs $0.58-10.3% | — |
Based on last 12 quarters of dataView full earnings history →
THAR Peer Comparison
Tharimmune, Inc. (THAR) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HALO | 7.68B | 65.19 | 25.46 | 37.55% | 22.69% | 6.49% | ||
 PRTA | 566.86M | 10.53 | -2.32 | -92.84% | -260.92% | -49.88% | 0.05 | |
 ALDX | 104.08M | 1.73 | -1.84 | -87.71% | 0.22 | |||
 CLDX | 2.22B | 33.32 | -8.54 | -78.63% | -172.53% | -41.68% | 0.00 | |
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 RAPT | 295.54M | 58.01 | -2.28 | -61.81% | 0.02 | |||
 MDGL | 12.27B | 534.86 | -41.62 | 432.05% | -27.32% | -50.15% | 0.59 | |
 AKBA | 316.54M | 1.18 | -56.73 | 47.46% | -8.83% | -62.72% | 6.63 |
Compare THAR vs Peers
Tharimmune, Inc. (THAR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
THAR Income Statement
Tharimmune, Inc. (THAR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - |
| Operating Expenses | 994.54K | 1.52M | 3.21M | 6.88M | 9.46M | 12.43M | 10.34M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 625.81K | 671.88K | 1.37M | 4.6M | 5.9M | 6.04M | 6.84M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 368.73K | 847.27K | 1.84M | 2.28M | 3.56M | 6.39M | 3.5M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -994.54K▲ 0% | -1.52M▼ 52.7% | -3.21M▼ 111.2% | -6.88M▼ 114.5% | -9.46M▼ 37.4% | -12.43M▼ 31.5% | -10.34M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -52.75% | -111.17% | -114.52% | -37.39% | -31.5% | - |
| EBITDA | -1.45M | -2.17M | -1.38M | -6.65M | -9.3M | -12.66M | -10.29M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -49.67% | 36.64% | -383.76% | -39.82% | -36.05% | 5.14% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 228.49K | 152.63K | -222.54K | 0 |
| EBIT | -1.45M | -2.17M | -1.38M | -6.88M | -9.3M | -12.21M | -10.29M |
| Net Interest Income | -75.07K | -246.53K | -831.28K | -1.59M | 136.13K | 236.22K | 19.63K |
| Interest Income | 0 | 0 | 0 | 0 | 152.63K | 249.91K | 44.66K |
| Interest Expense | 75.07K | 246.53K | 831.28K | 1.59M | 16.5K | 13.68K | 25.04K |
| Other Income/Expense | -530.93K | -898.22K | 1M | -1.59M | 136.13K | 236.22K | 19.63K |
| Pretax Income | -1.53M▲ 0% | -2.42M▼ 58.5% | -2.21M▲ 8.7% | -8.47M▼ 284.0% | -9.32M▼ 10.0% | -12.2M▼ 30.9% | -10.32M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -1.53M▲ 0% | -2.42M▼ 58.5% | -2.21M▲ 8.7% | -8.47M▼ 284.0% | -9.32M▼ 10.0% | -12.2M▼ 30.9% | -10.32M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -58.47% | 8.72% | -283.99% | -9.98% | -30.89% | 4.9% |
| Net Income (Continuing) | -1.53M | -2.42M | -2.21M | -8.47M | -9.32M | -12.2M | -10.32M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -55.56▲ 0% | -88.05▼ 58.5% | -72.81▲ 17.3% | -280.77▼ 285.6% | -107.08▲ 61.9% | -9.41▲ 91.2% | -1.65▲ 0% |
| EPS Growth % | - | -58.48% | 17.31% | -285.62% | 61.86% | 91.21% | 64.16% |
| EPS (Basic) | -55.56 | -88.05 | -72.81 | -280.77 | -107.08 | -9.41 | - |
| Diluted Shares Outstanding | 27.45K | 27.45K | 30.3K | 30.18K | 87.03K | 1.3M | 6.24M |
| Basic Shares Outstanding | 27.45K | 27.45K | 30.3K | 30.18K | 87.03K | 1.3M | 6.24M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
THAR Balance Sheet
Tharimmune, Inc. (THAR) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 40.88K | 294.8K | 621.68K | 6.69M | 10.95M | 3.72M | 7.7M |
| Cash & Short-Term Investments | 38.28K | 191.85K | 4.36K | 6.51M | 10.94M | 3.56M | 7.61M |
| Cash Only | 38.28K | 191.85K | 4.36K | 6.51M | 10.94M | 3.56M | 7.61M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 546.65K | 178.09K | 11.04K | 162.26K | 89.04K |
| Total Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 40.88K▲ 0% | 294.8K▲ 621.1% | 621.68K▲ 110.9% | 6.69M▲ 975.9% | 10.95M▲ 63.7% | 3.72M▼ 66.0% | 7.7M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 621.11% | 110.88% | 975.9% | 63.66% | -66% | -170.05% |
| Total Current Liabilities | 1.13M | 2.73M | 4.53M | 1.14M | 1.82M | 2.41M | 1.54M |
| Accounts Payable | 241.41K | 514.83K | 1.46M | 954.5K | 908.58K | 1.09M | 659.25K |
| Days Payables Outstanding | - | - | - | - | - | - | - |
| Short-Term Debt | 430.6K | 563.42K | 1.39M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 126.18K | 1.33M | 980.23K | 0 | 0 | 1.32M | 885.3K |
| Current Ratio | 0.04x | 0.11x | 0.14x | 5.84x | 6.03x | 1.54x | 1.54x |
| Quick Ratio | 0.04x | 0.11x | 0.14x | 5.84x | 6.03x | 1.54x | 1.54x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 532.77K | 1.29M | 772.9K | 0 | 0 | 0 | 0 |
| Long-Term Debt | 532.77K | 1.29M | 772.9K | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.66M | 4.01M | 5.31M | 1.14M | 1.82M | 2.41M | 1.54M |
| Total Debt | 963.37K | 1.85M | 2.17M | 0 | 0 | 0 | 0 |
| Net Debt | 925.09K | 1.66M | 2.16M | -6.51M | -10.94M | -3.56M | -7.61M |
| Debt / Equity | - | - | - | - | - | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | 0.74x |
| Interest Coverage | -13.25x | -6.16x | -3.86x | -4.32x | -572.87x | -908.64x | -411.14x |
| Total Equity | -1.62M▲ 0% | -3.72M▼ 129.2% | -4.68M▼ 26.0% | 5.54M▲ 218.3% | 9.13M▲ 64.7% | 1.31M▼ 85.7% | 6.15M▲ 0% |
| Equity Growth % | - | -129.17% | -26.02% | 218.33% | 64.72% | -85.68% | -187.78% |
| Book Value per Share | -59.09 | -135.41 | -154.59 | 183.70 | 104.92 | 1.01 | 0.99 |
| Total Shareholders' Equity | -1.62M | -3.72M | -4.68M | 5.54M | 9.13M | 1.31M | 6.15M |
| Common Stock | 628 | 636 | 636 | 46 | 1.18K | 198 | 721 |
| Retained Earnings | -2.09M | -4.7M | -6.91M | -15.38M | -24.7M | -36.9M | -43.4M |
| Treasury Stock | 0 | 0 | 0 | -69.97K | -69.97K | -69.97K | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
THAR Cash Flow Statement
Tharimmune, Inc. (THAR) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -706.11K | -1.08M | -1.09M | -6.56M | -7.3M | -10.9M | -10.9M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -52.73% | -0.72% | -503.73% | -11.32% | -49.34% | -26.71% |
| Net Income | -1.53M | -2.42M | -2.21M | -8.47M | -9.32M | -12.2M | -10.32M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 92.01K | 234.58K | 1.24M | 800.7K | 831.86K | 710.31K | 1.52M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 484.66K | 797.04K | -1.17M | 1.68M | 350K | 20.55K | 100.42K |
| Working Capital Changes | 242.69K | 307.32K | 1.05M | -569.11K | 837.13K | 564.71K | -18.2K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 15.76K | 306.57K | 580.85K | -141.17K | -45.93K | 181.09K | 301.26K |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 708.38K | 1.23M | 898.75K | 13.06M | 11.72M | 3.53M | 11.56M |
| Debt Issued (Net) | 580.88K | 1.23M | 1.08M | -14.64K | 0 | 0 | -35.7K |
| Equity Issued (Net) | 127.5K | 0 | 0 | 13.6M | 12.23M | 4.19M | 13.19M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -69.97K | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -179.27K | -521.29K | -510K | -661.73K | -1.59M |
| Net Change in Cash | 38.28K▲ 0% | 153.57K▲ 301.2% | -187.5K▼ 222.1% | 6.51M▲ 3570.0% | 4.42M▼ 32.0% | -7.38M▼ 266.7% | 2.84M▲ 0% |
| Free Cash Flow | -706.11K▲ 0% | -1.08M▼ 52.7% | -1.09M▼ 0.7% | -6.56M▼ 503.7% | -7.3M▼ 11.3% | -10.9M▼ 49.3% | -8.72M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -52.73% | -0.72% | -503.73% | -11.32% | -49.34% | 6.07% |
| FCF per Share | -25.72 | -39.28 | -35.84 | -217.31 | -83.88 | -8.41 | -8.41 |
| FCF Conversion (FCF/Net Income) | 0.46x | 0.45x | 0.49x | 0.77x | 0.78x | 0.89x | 0.85x |
| Interest Paid | 0 | 0 | 0 | 0 | 16.5K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
THAR Key Ratios
Tharimmune, Inc. (THAR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -1973.37% | -127.01% | -233.69% | -588.4% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | 446.2% |
| Debt / Equity | - | - | - | - | - | 0.00x |
| Interest Coverage | -6.16x | -3.86x | -4.32x | -572.87x | -908.64x | -411.14x |
| FCF Conversion | 0.45x | 0.49x | 0.77x | 0.78x | 0.89x | 0.85x |
THAR SEC Filings & Documents
Tharimmune, Inc. (THAR) SEC filings — annual & quarterly reports (10-K, 10-Q)
THAR Frequently Asked Questions
Tharimmune, Inc. (THAR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tharimmune, Inc. (THAR) grew revenue by 0.0% over the past year. Growth has been modest.
Tharimmune, Inc. (THAR) reported a net loss of $10.3M for fiscal year 2024.
Dividend & Returns
Tharimmune, Inc. (THAR) has a return on equity (ROE) of -233.7%. Negative ROE indicates the company is unprofitable.
Tharimmune, Inc. (THAR) had negative free cash flow of $8.7M in fiscal year 2024, likely due to heavy capital investments.
Explore More THAR
Tharimmune, Inc. (THAR) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates